Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
Br J Haematol
; 139(3): 434-8, 2007 Nov.
Article
em En
| MEDLINE
| ID: mdl-17910634
ABSTRACT
Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mouse calvarial cultures; this effect was blocked by dickkopf 1(Dkk1), an antagonist of Wnt signalling implicated in myeloma bone disease. Bortezomib inhibited Dkk1 expression in calvariae and bone marrow-derived stromal cells, suggesting a novel mechanism by which bortezomib exerts its effects in bone. Clinical trials in patients with myeloma bone disease are needed to validate these results.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteogênese
/
Inibidores de Proteases
/
Pirazinas
/
Ácidos Borônicos
/
Antineoplásicos
Limite:
Animals
Idioma:
En
Revista:
Br J Haematol
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos